Symbiosis Pharmaceutical Services has expanded its sterile biologics manufacturing facility in Scotland, UK by 25%.
 
The company has invested more than $1.9 million in the expansion of its Stirling site, doubling its current footprint with an additional 8,000 sq.-ft. of space to house administrative, management and operational teams, as well as the expansion of its manufacturing space and its supporting services infrastructure. 
 
The new operational area also provides additional capacity for GMP-compliant manufacturing services for supply chain management, additional temperature-controlled storage, and the company’s first automated labelling and packaging equipment. 
 
Colin MacKay, chief executive officer at Symbiosis said, “This represents another exciting step for Symbiosis which allows the company to continue to leverage its expertise in small scale clinical and commercial sterile manufacturing to drive future growth. The additional space has allowed us to increase our headcount from 60 to 90 employees in line with both customer demand and our ongoing growth strategy.
 
“The investment in the new facility is driven by the significant organic growth of the company as a result of its continued success in the niche market of sterile manufacturing of advanced therapeutic medicinal products (ATMPs) such as viral vector and other biopharmaceuticals. our customer base has grown by more than 25% in 2019 alone.”
 
The expanded facility, which was recently completed and is now fully operational, has been part-funded by a successful Innovate UK grant from the UK Government aimed at strengthening the UK’s viral vector biopharmaceutical drug development and manufacturing supply chain.